The European Association of Euro-Pharmaceutical Companies (EAEPC) is the professional and representative voice of pharmaceutical parallel trade in Europe. Through national associations and individual company membership, it encompasses over 70 firms from 16 countries in the European Economic Area (EEA). All products handled by EAEPC members have national or EU regulatory approval and are exclusively sourced from and sold to EEA countries using authorised trade channels.

EAEPC's primary aims are to safeguard the free movement of medicines, as laid down in Article 28 EC, and to counteract any attempts to restrict the freedom of choice for the consumer through trading patterns in breach of Articles 81 EC Treaty & 82 EC Treaty. The Association believes that free trade will lead to improvements in health standards through the provision of innovative medicines at lower cost, benefiting statutory healthcare systems, other third-party payers, and the public as both patients and taxpayers, as well as assisting the EU to achieve its objective of a single, internal market.

As a professional body, the EAEPC mission is to review, evaluate and react to all developments that affect parallel trade with medicines, to keep its members informed and involved, and to represent their interests with appropriate organisations at national and European level.

The EAEPC and its national member organisations actively encourage co-operations - at an EU and national level - with all relevant and interested parties such as governments, authorities as well as professional and patient/consumer organisations.

For further information, go to www.eaepc.org